A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Monoclonal Antibody (mAb) in Patients With IPF (SAD).

NCT05513950 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

Idiopathic Pulmonary Fibrosis

Interventions

BIOLOGICAL: CHF10067 starting dose -- 1000mg (Cohort A)
BIOLOGICAL: CHF10067 intermediate dose -- 2000mg (Cohort B)
BIOLOGICAL: CHF10067 high dose -- 3000mg (Cohort C)
DRUG: Placebo

Sponsor

Chiesi Farmaceutici S.p.A.